Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologic therapy for colon cancer.

Aiwu Ruth He1, John Marshall

  • 1Lombardi Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA.

Clinical Advances in Hematology & Oncology : H&O
|September 17, 2005
PubMed
Summary

Targeted biologic therapies like cetuximab and bevacizumab are advancing colorectal cancer treatment. Ongoing research aims to identify optimal patient candidates and clinical applications for these targeted agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial.

JAMA oncology·2026
Same author

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Journal of hepatology·2026
Same author

A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer.

NPJ precision oncology·2025
Same author

Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma.

JCO precision oncology·2025
Same author

A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels.

Cancer prevention research (Philadelphia, Pa.)·2025
Same author

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.

Journal of hepatology·2025

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Targeted biologic therapy is a rapidly advancing area in cancer treatment.
  • The US Food and Drug Administration has approved key biologic agents for colorectal cancer therapy.

Purpose of the Study:

  • To review the current landscape of targeted biologic therapies in colorectal cancer.
  • To discuss the ongoing research defining patient selection and clinical utility of these agents.

Main Methods:

  • Review of current preclinical and clinical studies on targeted biologic therapies.
  • Analysis of approved agents such as cetuximab and bevacizumab.

Main Results:

  • Cetuximab (anti-endothelial growth factor receptor) and bevacizumab (anti-vascular endothelial growth factor) are established treatments.
  • Research is actively defining patient populations that benefit most from these therapies.

Conclusions:

  • Further research is essential for optimizing the use of current biologic agents.
  • Continued studies will facilitate the development of novel targeted therapies for colon cancer.

Related Experiment Videos